2010
DOI: 10.1517/14656561003698131
|View full text |Cite
|
Sign up to set email alerts
|

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

Abstract: PDE5i will remain the mainstay initial medical treatment for ED and will play a larger role in the treatment of other medical conditions. Novel formulations in this class will allow patients to select agents that best suit their needs.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
61
0
1

Year Published

2011
2011
2018
2018

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 73 publications
(63 citation statements)
references
References 70 publications
1
61
0
1
Order By: Relevance
“…PDE inhibitors that are in clinical use include PDE5 inhibitors for treatment of ED and pulmonary hypertension (23, 55,82,97,112,119,120,242,255,284,306,359), PDE3 inhibitors for treatment of intermittent claudication and acute cardiac failure (180,181,242,260), a PDE4 inhibitor for treatment of COPD (139), a nonspecific PDE inhibitor (theophylline) for treatment of asthma (22), and dipyridamole, a relatively nonspecific PDE inhibitor for prevention of blood clotting following stroke or heart valve replacement (51, 91). Many new PDE inhibitors are being developed to provide improved treatment of these and other maladies.…”
Section: Overview Of the 11 Families And Isoenzymes Within Familiementioning
confidence: 99%
“…PDE inhibitors that are in clinical use include PDE5 inhibitors for treatment of ED and pulmonary hypertension (23, 55,82,97,112,119,120,242,255,284,306,359), PDE3 inhibitors for treatment of intermittent claudication and acute cardiac failure (180,181,242,260), a PDE4 inhibitor for treatment of COPD (139), a nonspecific PDE inhibitor (theophylline) for treatment of asthma (22), and dipyridamole, a relatively nonspecific PDE inhibitor for prevention of blood clotting following stroke or heart valve replacement (51, 91). Many new PDE inhibitors are being developed to provide improved treatment of these and other maladies.…”
Section: Overview Of the 11 Families And Isoenzymes Within Familiementioning
confidence: 99%
“…The molecular mechanisms involved have been reviewed in detail elsewhere (Francis et al, 2010). PDE5 inhibitors are currently first-line treatment of ED (see section VIII.C), and several new selective PDE5 inhibitors are in different stages of development or have already been introduced clinically (Hatzimouratidis and Hatzichristou, 2008;Dorsey et al, 2010;Eardley et al, 2010).…”
Section: J Nitric Oxide and Cgmp Signalingmentioning
confidence: 99%
“…Estos medicamentos son efectivos antes del acto sexual, pero no logran mejorar las erecciones espontáneas y su efecto es esencialmente limitado en el tiempo (7,24). Hasta 30% de los pacientes presentan efectos adversos de moderados a graves o tienen contraindicaciones para la toma de estos medicamentos, entre ellas, los intolerantes a los efectos secundarios (cefalea principalmente) y los que toman nitratos para la angina de pecho (25,26).…”
Section: Tratamientounclassified